AMAL Therapeutics is a Swiss biotech developing therapeutic vaccines, and aiming at overcoming the challenges around effective anti-cancer therapy by stimulating the immune system in a unique way, to create immunological memory. AMAL joined the Boehringer Ingelheim group of companies in 2019.
Products, services, technology
KISIMA®, a novel peptide/protein-based immunisation technology platform, enables the assembly within one chimeric fusion protein of 3 elements essential to generate potent immunity.
- http://www.amaltherapeutics.com
- +41 22 379 46 88
- contact@amaltherapeutics.com
